Stent Choice: Are Your Preferences Heard?
"Unveiling the disconnect between patient values and medical decisions in coronary stenting."
Choosing the right coronary stent—a tiny mesh tube that props open clogged arteries—is a critical decision for individuals with heart disease. While doctors weigh factors like the severity of the blockage and the patient's overall health, a recent study highlights a concerning disconnect: are patient preferences truly being considered?
Published in Catheterization and Cardiovascular Interventions, the study by Quintar et al. investigated how patients prioritize various outcomes associated with different types of stents—drug-eluting stents (DES) and bare-metal stents (BMS). DES reduce the risk of artery re-narrowing but require longer-term use of anti-clotting medications. BMS, on the other hand, carry a higher risk of re-narrowing but require less medication.
The study revealed that while patients have distinct concerns—such as avoiding repeat procedures, minimizing medication costs, and reducing the risk of bleeding—these preferences often don't align with the type of stent they ultimately receive. This raises questions about the extent to which shared decision-making is truly happening in cardiology.
Evidence for Tailored Stent Choice
Research on patient-tailored stent choice examines the efficacy and safety of coronary stents in specific procedural and clinical scenarios. In one preference study, complete information about factors affecting stent choice was available for 311 of 317 participating patients, while final-stent information was missing for 15 patients. Participants evaluated consequences including repeat procedures, daily medication burden, medication costs, bleeding risk, and delays to future surgery or dental work. A 2025 individual-patient-data meta-analysis reported that paclitaxel-coated balloon angioplasty showed mid-term angiographic or clinical non-inferiority to drug-eluting stents in randomized trials involving de novo small-vessel coronary artery disease.
Shared Decisions Without a Single Standard
Because stent-related trade-offs can affect patients’ experiences and outcomes, patients should be involved in the decision-making process, yet the cited source reports that fewer than one-third discuss stent choices with their doctors. Research has assessed coronary-revascularization preferences using rating, ranking, standard-gamble, and discrete-choice methods. This variety highlights the absence of a gold-standard method for measuring preferences. A shared-decision-making tool with decision coaching improved patient education, participation, and satisfaction, but did not change the type of stent used.
From Bare-Metal Stents to Iterative Innovation
The history of coronary stents is characterized by technical breakthroughs and continuing efforts to assess their clinical impact. The introduction of bare-metal stents helped usher in the revolution of percutaneous coronary intervention and a period of continual, iterative innovation. Subsequent technological advances have produced substantial improvements in devices that are now described as the gold standard for treating coronary artery disease. Recent reviews also examine how stent generations have evolved alongside changes in patient demographics, comorbidities, and clinical outcomes.
Preference vs. Practice: The Stent Selection Gap
In the Quintar et al. study, researchers surveyed 317 patients prior to diagnostic angiography, asking them to rate the importance of various potential consequences of stent choice. These included the need for repeat procedures, the number of daily medications, medication costs, risk of bleeding, and the need to delay future surgeries or dental work.
- 14.4% of patients ranked avoiding repeat procedures as their top priority.
- 20.6% prioritized other factors, such as medication burden or bleeding risk.
- A significant 65% considered avoiding repeat procedures as equally important to other concerns.
Long-Term Device Outcomes
Recent research identifies a knowledge gap in longitudinal monitoring of patient outcomes caused by coronary-stent devices. Existing evidence has extensively examined perioperative outcomes for bare-metal stents, drug-eluting stents, and bioresorbable drug-eluting stents, but device-related outcomes over longer periods remain less well characterized. A 2025 comparison reported that newer polymer-free titanium-nitride-oxide, polymer-permanent everolimus, and zotarolimus stents significantly reduced long-term ischemic events compared with polymer-permanent sirolimus. A separate analysis examined contemporary procedural advances and clinical outcomes in coronary angioplasty and stent placement at Mayo Clinic.
Limits of Personalization
Stent selection cannot be treated as a universally settled choice because the most suitable option may depend on clinical circumstances, procedural factors, and the outcomes a patient values. Evidence and preferences may not align, and a patient’s participation in discussion does not necessarily change the device selected. These limitations support cautious, individualized decision-making rather than assuming that one stent strategy will serve every patient.
Comparing DCB and DES Strategies
In acute coronary syndrome, percutaneous coronary intervention may involve either a drug-coated balloon or a drug-eluting stent. A 2025 meta-analysis specifically set out to compare the efficacy and safety of these approaches in patients with acute coronary syndrome. Guidance on choosing among drug-eluting stents, bare-metal stents, and polymer-free stents emphasizes that the decision should be personalized. The same source also highlights imaging, post-dilation, and careful stent sizing as ways to optimize procedural outcomes.
Empowering Patients: A Call for Shared Decision-Making
The study underscores the importance of actively involving patients in the stent selection process. As Dr. Blankenship points out, simply asking patients to rate the importance of general consequences isn't enough. Patients need clear, personalized information about the marginal risks and benefits of each stent type in their specific situation.
Aligning Treatment With Patient Priorities
Evidence on stent choice points to a meaningful gap between what patients value and which stents they receive. The Quintar study found that some patients prioritized avoiding repeat procedures, while others placed greater importance on minimizing medication burden or bleeding risk. Qualitative interviews with patients who received elective stents for stable angina explored how they understood the benefits and risks of treatment. Together, these findings support conversations that explicitly address the outcomes patients consider most important.
Monitoring New Patterns of Risk
The coronary-stent field continues to focus on devices that keep narrowed or blocked arteries open and restore blood flow to the heart. Future evaluation will also need to account for contemporary patterns of stent thrombosis. A U.S. nationwide registry study examined PCI performed for stent thrombosis among patients presenting with acute myocardial infarction from April 2018 through June 2023. Its focus on patient characteristics and in-hospital outcomes illustrates the importance of tracking real-world complications alongside technological development.
Variation in Care
Stent decisions occur within a complex clinical system in which evidence, procedural circumstances, available devices, and patient priorities may not always point in the same direction. Patients may receive detailed information yet still experience limited influence over the final choice. Addressing this challenge likely requires more consistent communication and clearer attention to the trade-offs that matter to individual patients.
What Patients Live With
For patients, stent choice can involve more than the immediate procedure. Concerns may include repeat interventions, daily medicines, medication costs, bleeding, and postponement of surgery or dental work. These practical consequences can shape how people understand the value and burden of treatment. A patient-centered discussion should therefore make room for both clinical considerations and everyday priorities.
For instance, understanding the actual cost difference between DES (including the cost of longer-term anti-clotting medication) and BMS, or the precise increase in restenosis risk with BMS, is crucial for informed decision-making. Tools like PREDICT can help facilitate these conversations.
Ultimately, the goal is to move beyond a one-size-fits-all approach and ensure that stent choices reflect individual patient values and priorities. This requires open communication, a willingness to explore patient concerns, and a commitment to shared decision-making in interventional cardiology.